MORF Stock Overview
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Morphic Holding, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.51 |
| 52 Week High | US$63.08 |
| 52 Week Low | US$19.35 |
| Beta | 1.42 |
| 1 Month Change | -18.85% |
| 3 Month Change | 3.27% |
| 1 Year Change | -36.28% |
| 3 Year Change | -51.26% |
| 5 Year Change | n/a |
| Change since IPO | 52.83% |
Recent News & Updates
Recent updates
We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20
Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business
Aug 05Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Apr 05Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)
Mar 09Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?
Feb 24How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?
Jan 20Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Dec 16Shareholder Returns
| MORF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | -4.2% | -3.7% |
| 1Y | -36.3% | -2.0% | 20.5% |
Return vs Industry: MORF underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: MORF underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| MORF volatility | |
|---|---|
| MORF Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MORF's share price has been volatile over the past 3 months.
Volatility Over Time: MORF's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 121 | Bruce Rogers | www.morphictx.com |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company’s products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.
Morphic Holding, Inc. Fundamentals Summary
| MORF fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$152.09m |
| Revenue (TTM) | US$521.00k |
2,642x
P/S Ratio-9.1x
P/E RatioIs MORF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MORF income statement (TTM) | |
|---|---|
| Revenue | US$521.00k |
| Cost of Revenue | US$140.38m |
| Gross Profit | -US$139.86m |
| Other Expenses | US$12.23m |
| Earnings | -US$152.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | -26,845.11% |
| Net Profit Margin | -29,192.90% |
| Debt/Equity Ratio | 0% |
How did MORF perform over the long term?
See historical performance and comparison